Swedish Orphan Biovitrum develops and markets pharmaceutical treatments for rare diseases. The company focuses on hematology, immunology, and genetic disorders, with key products addressing hemophilia and other specialty conditions. It operates through direct sales in Europe and partnerships in other regions to reach patients with limited treatment options.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 6,465 | — | 875 | -4.7% |
| Q2 2025 | 6,175 | — | 636 | 159.9% |
| Q4 2025 | 7,821 | — | 1,861 | 36.1% |
| Q1 2026 | 7,183 | 11.1% | 1,318 | 50.6% |
| Q2 2026 | 7,842 | 27% | 1,097 | 72.5% |
All markets — KeepWinning global stock screener
Other companies on Stockholm: Evolution AB (publ) (EVO), Boliden AB (publ) (BOL), L E Lundbergföretagen AB (publ) (LUND B), Lifco AB (publ) (LIFCO B), Investment AB Latour (publ) (LATO B), AB SKF (publ) (SKF A)